THE CHANDLER PROJECT JOINS GLOBAL GENES RARE-X PROGRAM
John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It arises from a defect in the process of bone growth in…
SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QEDβs plans to evaluate a…
Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you are all doing well, are safe, and are using this…
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy ofΒ infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in…
QED Therapeutics, Inc. (βQEDβ), a subsidiary of BridgeBio Pharma, Inc. (βBridgeBioβ) focuses on bringing medicine to people living with conditions that are caused by changes in fibroblast growth factor receptor…